NOXCOVID-1 design, page-6

I absolutely agree that a large randomised trial will be required before we can be certain that Veyonda is effective. Where we disagree, perhaps, is whether NOXCOVID-1 will give an indication of efficacy.

Patients in Moldova and Ukraine are unlikely to have access to remdisivir, and the aim of the trial is to stop patients progressing to the point of needing dexamethasone., so a positive response in patients who do not receive these drugs would be a good start, imo. Analysis of before-and-after plasma samples in the USA would give a further indication of efficacy.

The primary objectives of the trial are to confirm safety, and to establish maximum tolerated dose; but Noxopharm also wants to know whether it should jump into a large, expensive trial. If patients respond to treatment, they will be happy and so will I.